{"url":"https://whatshealthyandwhy.com/omega-3/heart-health","path":"/omega-3/heart-health","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/omega-3/heart-health.json","markdown":"https://whatshealthyandwhy.com/omega-3/heart-health.md"},"topic":{"slug":"omega-3","name":"Omega-3 Fatty Acids","url":"https://whatshealthyandwhy.com/omega-3"},"slug":"heart-health","order":2,"title":"Omega-3s and Heart Health","question":"Do omega-3s protect your heart?","answer":"Omega-3s likely modestly lower heart disease risk, with the clearest benefit from high-dose purified EPA in people with high triglycerides already on statins.","description":"How EPA and DHA support cardiovascular health and what the research shows","confidence":3,"confidenceNote":"REDUCE-IT (4 g) cut events 25% but VITAL (1 g) missed its main outcome; a 13-trial meta-analysis found 8% lower CHD risk.","evidenceSummary":{"rctCount":2,"observationalCount":0,"metaAnalysisCount":1,"totalParticipants":"~127,000","replicated":true,"newestStudyYear":2024},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Supplements & Vitamins","subcategorySlug":"supplements","url":"https://whatshealthyandwhy.com/explore/good-for-you/supplements"},"actions":["Eat fish at least twice a week, as the American Heart Association recommends [3].","If you have heart disease or high triglycerides despite a statin, ask your doctor about omega-3 therapy; prescription products differ from supplements [4].","Check supplement labels for actual EPA and DHA per serving; benefits became clearer above 1 g a day [5]."],"cautions":["Do not start high-dose omega-3 on your own: the 4 g/day REDUCE-IT dose was prescription purified EPA used in a medical trial [1].","In healthy adults, 1 g a day did not significantly reduce overall cardiovascular events or stroke [2]."],"simpleText":"One of the best-studied benefits of omega-3 fatty acids is their effect on heart health. Eating fish regularly or taking EPA and DHA supplements has been linked to lower risk of heart attacks, healthier blood pressure, and improved cholesterol profiles.\n\nThe American Heart Association recommends eating fish at least twice per week as part of a heart-healthy diet [3]. This isn't just a general wellness suggestion -- it's backed by large clinical trials involving tens of thousands of participants.\n\nIf you're wondering whether omega-3s are worth paying attention to for your heart, the short answer is yes, especially EPA.","mediumText":"The cardiovascular benefits of omega-3s operate through several mechanisms. EPA and DHA lower blood triglyceride levels, a well-established risk factor for heart disease. At therapeutic doses (2-4 grams per day), they can reduce triglycerides by 20-30% [4]. They also modestly reduce blood pressure, slow the buildup of arterial plaque, and reduce the likelihood of dangerous heart rhythm disturbances.\n\nThe landmark REDUCE-IT trial (2019) showed that 4 grams per day of purified EPA (icosapent ethyl) reduced major cardiovascular events by 25% in patients already on statin therapy who had elevated triglycerides [1]. This was a significant finding because it demonstrated benefit on top of existing standard care.\n\nThe VITAL trial, another large study involving over 25,000 participants, found that 1 gram per day of combined EPA and DHA reduced the risk of heart attacks by 28%, though it did not significantly reduce overall cardiovascular events or stroke [2]. The benefit was most pronounced in people who ate less than 1.5 servings of fish per week at baseline.\n\nTwo recent meta-analyses found that the benefit grows with dose: Hu et al. (13 trials) reported linear dose-response relationships for total cardiovascular disease and major vascular events [6], and Bernasconi et al. (40 trials) found the effect dose dependent for cardiovascular events and heart attack [5].\n\nNot all findings are uniformly positive, and the effects depend on dose, form, and baseline risk. But the weight of evidence supports meaningful cardiovascular benefit, particularly from EPA.","deepText":"The cardiovascular evidence for omega-3 fatty acids has evolved considerably. Early observational studies of fish-eating populations (notably Greenland Inuit) suggested dramatic cardioprotection, but the interventional trial landscape is more nuanced.\n\nThe REDUCE-IT trial (Bhatt et al., 2019) randomized 8,179 patients with established cardiovascular disease or diabetes plus additional risk factors, all on statin therapy with residual hypertriglyceridemia (135-499 mg/dL), to icosapent ethyl 4 g/day or mineral oil placebo. The primary composite endpoint (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina) was reduced by 25% (HR 0.75; 95% CI 0.68-0.83; p<0.001). Key secondary endpoints including cardiovascular death were also significantly reduced [1]. The magnitude of benefit exceeded what triglyceride lowering alone would predict, suggesting pleiotropic mechanisms including anti-inflammatory, antithrombotic, and membrane-stabilizing effects.\n\nThe VITAL trial (Manson et al., 2019) took a different approach, studying primary prevention in 25,871 generally healthy adults randomized to 1 g/day of combined EPA+DHA or placebo using a 2x2 factorial design with vitamin D. While the primary composite endpoint of major cardiovascular events was not significantly reduced (HR 0.92; 95% CI 0.80-1.06), the prespecified secondary endpoint of total MI was reduced by 28% (HR 0.72; 95% CI 0.59-0.90). Subgroup analyses showed greater benefit among African Americans and those with low baseline fish intake [2].\n\nThe AHA Science Advisory (Siscovick et al., 2017, updated 2019) affirmed that prescription omega-3 therapy is reasonable for reducing triglycerides at doses of 4 g/day, and that 1 g/day EPA+DHA is reasonable for secondary prevention of coronary heart disease and sudden cardiac death [4]. The Advisory notes the distinction between prescription-grade concentrated formulations and over-the-counter supplements, which vary in EPA/DHA content and purity.\n\nHu et al. (2019) conducted an updated meta-analysis of 13 randomized trials encompassing 127,477 participants [6]. In the analysis that excluded REDUCE-IT, marine omega-3 supplementation was associated with significantly lower risk of myocardial infarction (RR 0.92; 95% CI 0.86-0.99), CHD death (RR 0.92; 95% CI 0.86-0.98), total CHD (RR 0.95; 95% CI 0.91-0.99), CVD death (RR 0.93; 95% CI 0.88-0.99), and total CVD (RR 0.97; 95% CI 0.94-0.99), and risk reductions appeared to be linearly related to marine omega-3 dose. Bernasconi et al. (2021) updated and expanded an earlier meta-analysis to 40 trials with 135,267 participants: EPA/DHA supplementation was associated with reduced risk of myocardial infarction (RR 0.87; 95% CI 0.80-0.96), CHD events (RR 0.90; 95% CI 0.84-0.97), fatal myocardial infarction (RR 0.65; 95% CI 0.46-0.91) and CHD mortality (RR 0.91; 95% CI 0.85-0.98), but not overall CVD events (RR 0.95; 95% CI 0.90-1.00), and the effect was dose dependent for CVD events and heart attack [5]. This dose-response relationship may help reconcile earlier null trials that used lower doses.\n\nThe American Heart Association continues to recommend at least two servings of fatty fish per week for the general population, and to consider omega-3 supplementation for patients with prevalent CHD or heart failure [3].","deepTruncated":false,"references":[{"id":"1","title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","authors":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM","year":2019,"journal":"New England Journal of Medicine","pmid":"30415628","url":"https://pubmed.ncbi.nlm.nih.gov/30415628/"},{"id":"2","title":"Marine omega-3 fatty acids and prevention of cardiovascular disease and cancer","authors":"Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE","year":2019,"journal":"New England Journal of Medicine","pmid":"30415637","url":"https://pubmed.ncbi.nlm.nih.gov/30415637/"},{"id":"3","title":"Fish and Omega-3 Fatty Acids","authors":"American Heart Association","year":2024,"journal":"American Heart Association","url":"https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/fats/fish-and-omega-3-fatty-acids"},{"id":"4","title":"Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association","authors":"Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM, Jacobson TA, Engler MB, Alger HM, Appel LJ, Mozaffarian D","year":2017,"journal":"Circulation","pmid":"28289069","url":"https://pubmed.ncbi.nlm.nih.gov/28289069/"},{"id":"5","title":"Effect of omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials","authors":"Bernasconi AA, Wiest MM, Lavie CJ, Milani RV, Laukkanen JA","year":2021,"journal":"Mayo Clinic Proceedings","pmid":"32951855","url":"https://pubmed.ncbi.nlm.nih.gov/32951855/"},{"id":"6","title":"Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants","authors":"Hu Y, Hu FB, Manson JE","year":2019,"journal":"Journal of the American Heart Association","pmid":"31567003","url":"https://pubmed.ncbi.nlm.nih.gov/31567003/"}],"wordCount":815,"source":{"path":"src/content/topics/omega-3/heart-health.md"},"citeAs":"“Do omega-3s protect your heart?.” What's Healthy and Why. https://whatshealthyandwhy.com/omega-3/heart-health","notice":"General information backed by peer-reviewed research, not medical advice."}